Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2019

View Archived Issues

Proof of concept of PRIT in peritoneal carcinomatosis presented

Metabolic problems are early event in Alzheimer's

BRAF fusion drug responses diverse but predictable

Optogenetically activated intrabodies modulate exogenous proteins

Slc7a7 knockout mice display features of lysinuric protein intolerance

Two novel mutations in the HIBCH gene linked to HIBCH deficiency

VWA2 identified as a novel autosomal recessive gene candidate in AD

Identification of first FA-T case caused by homozygous missense variants in UBE2T

First-in-human data presented for NJA-730

Suven Life Sciences presents preclinical data for SUVN-A6077

C-781: a promising compound for mechanical allodynia

Imugene provides update on its CF-33 oncolytic virus clinical program

First patient with IPF dosed in phase I study of IDL-2965

pH Pharma and Immunome collaborate to discover ADCs for cancer

FDA approves Stelara for the treatment of adults with moderate to severely active ulcerative colitis

i2020 Accelerator invests in research program at University of Turku for neurodegenerative diseases

Assertio Therapeutics announces FDA complete response letter for long-acting cosyntropin

Promising phase III data presented for somatrogon in children with growth hormone deficiency

OncoArendi Therapeutics divulges ARG1 and ARG2 inhibitors

Takeda Pharmaceutical patents CDK12 inhibitors

Japanese researchers synthesize new compounds for cancer

Sumitomo Dainippon Pharma identifies MEN1/MLL interaction inhibitors

Novartis describes new PROTACs

FDA approves Trikafta for cystic fibrosis

Biogen to pursue regulatory filing for aducanumab in early Alzheimer's disease

FDA clears IND for phase I study of RP-L301 for pyruvate kinase deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...